Access the full text.
Sign up today, get DeepDyve free for 14 days.
FT Bosman, F Carbeuri, RH Hruban, ND Theise (2010)
WHO classification of tumors of the digestive system
M. Mangum, F. Greco, J. Hainsworth, K. Hande, D. Johnson (1989)
Combined small-cell and non-small-cell lung cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 7 5
ME O’Brien, TE Ciuleanu, H Tsekov (2006)
Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancerJ Clin Oncol, 24
B. Brenner, Laura Tang, J. Shia, D. Klimstra, D. Kelsen (2007)
Small cell carcinomas of the gastrointestinal tract: clinicopathological features and treatment approach.Seminars in oncology, 34 1
K. Matsui, M. Kitagawa, A. Miwa, Y. Kuroda, M. Tsuji (1991)
Small cell carcinoma of the stomach: a clinicopathologic study of 17 cases.The American journal of gastroenterology, 86 9
O. Clark, A. Benson, J. Berlin, M. Choti, G. Doherty, P. Engstrom, J. Gibbs, M. Heslin, A. Kessinger, M. Kulke, L. Kvols, R. Salem, L. Saltz, M. Shah, S. Shibata, J. Strosberg, James Yao (2009)
NCCN Clinical Practice Guidelines in Oncology: neuroendocrine tumors.Journal of the National Comprehensive Cancer Network : JNCCN, 7 7
D. Maru, H. Khurana, A. Rashid, A. Correa, S. Anandasabapathy, S. Krishnan, R. Komaki, J. Ajani, S. Swisher, W. Hofstetter (2008)
Retrospective Study of Clinicopathologic Features and Prognosis of High-grade Neuroendocrine Carcinoma of the EsophagusThe American Journal of Surgical Pathology, 32
J. Pawel, J. Schiller, F. Shepherd, S. Fields, J. Kleisbauer, N. Chrysson, D. Stewart, P. Clark, M. Palmer, A. Depierre, J. Carmichael, J. Krebs, G. Ross, S. Lane, R. Gralla (1999)
Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 17 2
N. Hanna (2008)
Phase III Trial Comparing Supportive Care Alone With Supportive Care With Oral Topotecan in Patients With Relapsed Small-Cell Lung CancerYearbook of Oncology, 2008
S. Sundstrøm, R. Bremnes, S. Kaasa, U. Aasebø, R. Hatlevoll, R. Dahle, Nils Boye, Mari Wang, T. Vigander, J. Vilsvik, E. Skovlund, E. Hannisdal, S. Aamdal (2002)
Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 20 24
J. Pawel, A. Ardizzoni, N. Thatcher, T. Crofts, P. Wissel, G. Dane, G. Ross (2003)
P-569 The relationship between treatment-free interval (TFI) and outcomes to therapy in patients with relapsed Small Cell Lung Cancer (SCLC): A review of 631 patients treated with IV topotecan in 6 studiesLung Cancer, 41
(2010)
WHO classification of tumors of the digestive system, 4th edn. WHO Press, Geneva, pp
Taichi Isobe, S. Yanai, H. Kusaba, S. Yada, Yosuke Kuroda, S. Tamiya, T. Matsumoto, E. Baba, M. Harada (2009)
Effective Monotherapy with Amrubicin for a Refractory Extrapulmonary Small-Cell Carcinoma of the LiverCase Reports in Medicine, 2009
A. Inoue, S. Sugawara, K. Yamazaki, M. Maemondo, Toshiro Suzuki, K. Gomi, S. Takanashi, C. Inoue, M. Inage, H. Yokouchi, H. Watanabe, T. Tsukamoto, Y. Saijo, O. Ishimoto, F. Hommura, T. Nukiwa (2008)
Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0402.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 33
D. Ettinger, R. Jotte, P. Lorigan, Vicram Gupta, L. Garbo, C. Alemany, P. Conkling, D. Spigel, A. Dudek, C. Shah, R. Salgia, R. Mcnally, M. Renschler, J. Oliver (2010)
Phase II study of amrubicin as second-line therapy in patients with platinum-refractory small-cell lung cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 15
E. Mitry, E. Baudin, M. Ducreux, J. Sabourin, P. Rufié, T. Aparicio, P. Lasser, D. Elias, P. Duvillard, M. Schlumberger, P. Rougier (1999)
Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatinBritish Journal of Cancer, 81
H. Murakami, N. Yamamoto, T. Shibata, K. Takeda, Y. Ichinose, Y. Ohe, N. Yamamoto, Y. Takeda, S. Kudoh, S. Atagi, M. Satouchi, K. Kiura, N. Nogami, M. Endo, Hirokazu Watanabe, T. Tamura (2014)
A single-arm confirmatory study of amrubicin therapy in patients with refractory small-cell lung cancer: Japan Clinical Oncology Group Study (JCOG0901).Lung cancer, 84 1
K. Noda, Y. Nishiwaki, M. Kawahara, S. Negoro, T. Sugiura, A. Yokoyama, M. Fukuoka, K. Mori, Koshiro Watanabe, T. Tamura, Seiichiro Yamamoto, N. Saijo (2002)
Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer.The New England journal of medicine, 346 2
M. Asayama, N. Fuse, T. Yoshino, T. Yano, M. Tahara, T. Doi, S. Fujii, A. Ohtsu (2011)
Amrubicin for the treatment of neuroendocrine carcinoma of the gastrointestinal tract: a retrospective analysis of five casesCancer Chemotherapy and Pharmacology, 68
J. Pawel, R. Jotte, D. Spigel, M. O'Brien, M. Socinski, J. Mezger, M. Steins, L. Bosquée, Jeffrey Bubis, K. Nackaerts, J. Trigo, P. Clingan, W. Schütte, P. Lorigan, M. Reck, M. Dómine, F. Shepherd, Shaoyi Li, M. Renschler (2014)
Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 32 35
J. Eckardt, J. Pawel, J. Pujol, Z. Pápai, E. Quoix, A. Ardizzoni, R. Poulin, A. Preston, G. Dane, G. Ross (2007)
Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 25 15
Y. Sugimoto, Satomi Tsukahara, T. Oh‐hara, Leroy-Fong Liu, Takashi Tsuruo, Takashi Tsuruo (1990)
Elevated expression of DNA topoisomerase II in camptothecin-resistant human tumor cell lines.Cancer research, 50 24
(2011)
: Japan Clinical Oncology Group Study ( JCOG 0901 )
AMR showed evidence of clinical activity and safety when used for the treatment of EPNEC. It might be especially useful for populations with sensitive relapse.
Cancer Chemotherapy and Pharmacology – Springer Journals
Published: Apr 1, 2015
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.